The FDA has approved an influenza vaccine (FluLaval, GlaxoSmithKline) for the active immunization of patients 18 years of age and older against influenza virus subtypes A and B. This approval is a major step toward increasing the influenza vaccine supply in the U.S., following the introduction of GSK’s Fluarix before last year’s flu season.
The company added FluLaval to its portfolio of flu products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in 2005. Flu-Laval was granted fast-track review status by the FDA in July 2005. It is marketed under the name Fluviral in Canada.
FluLaval contains noninfectious killed viruses, and it cannot cause influenza. It will be available in 10-dose multidose vials. It is not indicated for use in children or for anyone with known systemic hypersensitivity reactions to egg proteins (in eggs or egg products), chicken proteins, or any component of FluLaval.